Abstract:The genomics revolution over the past three decades has led to great strides in rare disease (RD) research, which presents a major shift in global policy landscape. While RDs are individually rare, there are common challenges and unmet medical and social needs experienced by the RD population globally. The various disabilities arising from RDs as well as diagnostic and treatment uncertainty were demonstrated to have detrimental influence on the health, psychosocial, and economic aspects of RD families. Despite the collective large number of patients and families affected by RDs internationally, the general lack of public awareness and expertise constraints have neglected and marginalized the RD population in health systems and in health- and social-care policies. The current Coronavirus Disease of 2019 (COVID-19) pandemic has exposed the long-standing and fundamental challenges of the RD population, and has reminded us of the critical need of addressing the systemic inequalities and widespread disparities across populations and jurisdictions. Owing to the commonality in goals between RD movements and universal health coverage targets, the United Nations (UN) has highlighted the importance of recognizing RDs in policies, and has recently adopted the UN Resolution to promote greater integration of RDs in the UN agenda, advancing UN's commitment in achieving the 2030 Sustainable Development Goals of “leav[ing] no one behind.” Governments have also started to launch Genome Projects in their respective jurisdictions, aiming to integrate genomic medicine into mainstream healthcare. In this paper, we review the challenges experienced by the RD population, the establishment and adoption of RD policies, and the state of evidence in addressing these challenges from a global perspective. The Hong Kong Genome Project was illustrated as a case study to highlight the role of Genome Projects in enhancing clinical application of genomic medicine for personalized medicine and in improving equity of access and return in global genomics. Through reviewing what has been achieved to date, this paper will provide future directions as RD emerges as a global public health priority, in hopes of moving a step toward a more equitable and inclusive community for the RD population in times of pandemics and beyond.

Rare diseases: human genome research is coming home

A brief history of human disease genetics

Bedside Back to Bench: Building Bridges between Basic and Clinical Genomic Research

Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

The expanding diagnostic toolbox for rare genetic diseases

Rare and undiagnosed diseases: From disease-causing gene identification to mechanism elucidation

New Developments and Possibilities in Reanalysis and Reinterpretation of Whole Exome Sequencing Datasets for Unsolved Rare Diseases Using Machine Learning Approaches

Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases

Next-generation sequencing and bioinformatics in rare movement disorders

Bioinformatics of germline variant discovery for rare disease diagnostics: current approaches and remaining challenges

Rare diseases, spotlighting amyotrophic lateral sclerosis, Huntington’s disease, and myasthenia gravis: Insights from landscape analysis of current research

Leaving no patient behind! Expert recommendation in the use of innovative technologies for diagnosing rare diseases

Genome Sequencing for Diagnosing Rare Diseases

Progress in the diagnosis and treatment of rare diseases in the era of genomic medicine

From target discovery to clinical drug development with human genetics

[Rare diseases: unraveling the biological bases to find future therapies]

Big data and innovative bioinformatics approaches in personalized genomic medicine

Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases

Rare disease emerging as a global public health priority

Discovery of genetic risk factors for disease